Komori
TAUNS Laboratories (197A) · RiskMitigated

Dilution of share value through the exercise of stock acquisition rights

First written in FY2024. 2 of 4 entries say "Mitigated", first in FY2025. Latest entry: FY2026.

4entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024MaterialisedFY2025-H1MitigatedFY2025 – FY20262024: 120242025: 220252026: 12026
Same theme, other companies
Share dilution from the exercise of stock optionsA theme 384 companies write about · 384 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2017: 37 of 68 companies on the "Worse" side.

53 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 384 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026MitigatedAnnual report

    「As of the date of submission of this document, the number of potential shares represented by these stock acquisition rights was 1,088,259, equivalent to 1.02% of the 106,813,093 shares issued.」

    The potential dilution ratio declined from 4.56% in the previous fiscal year to 1.02%. In FY2026, 3,699,316 shares were issued upon the exercise of stock acquisition rights, reducing the remaining dilution exposure.
  2. FY2025MitigatedAnnual report

    「As of the date of filing this document, the number of potential shares represented by these stock acquisition rights was 4,730,578, equivalent to 4.56% of the 103,199,774 issued shares.」

    Although 2,992,370 shares were issued through the exercise of stock acquisition rights during the fiscal year, potential shares as of the filing date decreased from 7,037,371 to 4,730,578. Part of the dilution occurred, while the remaining potential dilution declined.
  3. FY2025-H1MaterialisedAnnual report

    「Change in the number of issued shares: 1,784,896 shares (Note) The increase resulted from the exercise of stock acquisition rights.」

    The exercise of stock acquisition rights resulted in the issuance of 1,784,896 shares, and part of the previously identified dilution risk materialized as an actual increase in shares. The remaining number of potential shares was not disclosed in this filing.
  4. FY2024First statedAnnual report

    「As of the date of filing this document, the number of potential shares represented by these stock acquisition rights was 7,037,371, equivalent to 6.98% of the 100,866,819 issued shares.」

    The company discloses the possibility of stock acquisition rights granted as incentives to officers and employees being exercised as a dilution risk.
Moved together

"IP and Technology Partnership Investments Toward the 10-Year Business Vision" moved the same way as this thread, in the same document, in 2 of its 4 moves.

22222★12345
  1. ★This thread
  2. 1IP and Technology Partnership Investments Toward the 10-Year Business Vision2×
  3. 2Impact of CITIC・Trustar Group’s Holdings and Disposal Policy2×
  4. 3Percentage of company vehicles that are hybrid vehicles2×
  5. 4Expansion of Overseas Distributors and Countries Covered by Regulatory Affairs2×
  6. 5Creating an attractive workplace environment, including parental leave and leave utilization2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for TAUNS Laboratories yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.